Dynamic Contrast-Enhanced MR Imaging of the Liver: Current Status and Future Directions

Magnetic Resonance Imaging Clinics of North America

Volumn 17, Issue 2, 2009, Pages 339-349

  Do, Richard Kinh Gian ^a   Rusinek, Henry ^a   Taouli, Bachir ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Dynamic contrast enhancement; Fibrosis; Hepatocellular carcinoma; Liver; Metastases; MR imaging; Perfusion

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOLINIUM; GADOLINIUM PENTETATE; PENTETIC ACID;

COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER METASTASIS; MEDICAL ASSESSMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; QUANTITATIVE ANALYSIS; REVIEW;

ANIMALS; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; LIVER; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; MATHEMATICS; PERFUSION IMAGING;

EID: 65249103337     PISSN: 10649689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mric.2009.01.009     Document Type: Review

References (54)

1. Afdhal N.H., and Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 99 6 (2004) 1160-1174
2. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 7 (2007) 2557-2576
3. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 11 (1996) 693-699
4. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 9319 (2002) 1734-1739
5. Llovet J.M., Fuster J., and Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10 2 Suppl 1 (2004) S115-S120
6. Pandharipande P.V., Krinsky G.A., Rusinek H., et al. Perfusion imaging of the liver: current challenges and future goals. Radiology 234 3 (2005) 661-673
7. Martinez-Hernandez A. The hepatic extracellular matrix. II. Electron immunohistochemical studies in rats with CCl4-induced cirrhosis. Lab Invest 53 (1985) 166-186
8. Richter S., Mucke I., Menger M.D., et al. Impact of intrinsic blood flow regulation in cirrhosis: maintenance of hepatic arterial buffer response. Am J Physiol Gastrointest Liver Physiol 279 2 (2000) G454-G462
9. Gulberg V., Haag K., Rossle M., et al. Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology 35 3 (2002) 630-634
10. Terayama N., Terada T., and Nakanuma Y. An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue. Histopathology 29 1 (1996) 37-43
11. Park Y.N., Kim Y.B., Yang K.M., et al. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 124 7 (2000) 1061-1065
12. Shimamura T., Saito S., Morita K., et al. Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens. J Gastroenterol Hepatol 15 6 (2000) 640-646
13. Takeda A., Stoeltzing O., Ahmad S.A., et al. Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 9 7 (2002) 610-616
14. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 26 (2006) 4293-4300
15. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): results of a Phase III randomized placebo-controlled trial (SHARP trial). In: 2007 ASCO Annual Meeting Proceedings Part I. Journal of Clinical Oncology 2007;25(18S).
16. Alberts S.R., and Wagman L.D. Chemotherapy for colorectal cancer liver metastases. Oncologist 13 10 (2008) 1063-1073
17. Siegel A.B., Cohen E.I., Ocean A., et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26 18 (2008) 2992-2998
18. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 4 (2008) 378-390
19. Provenzale J.M. Imaging of angiogenesis: clinical techniques and novel imaging methods. AJR Am J Roentgenol 188 1 (2007) 11-23
20. Weinreb J.C. Which study when? Is gadolinium-enhanced MR imaging safer than iodine-enhanced CT?. Radiology 249 1 (2008) 3-8
21. Marckmann P., Skov L., Rossen K., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 9 (2006) 2359-2362
22. Kanal E., Barkovich A.J., Bell C., et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol 188 6 (2007) 1447-1474
23. Thomsen H.S., Marckmann P., and Logager V.B. Update on nephrogenic systemic fibrosis. Magn Reson Imaging Clin N Am 16 4 (2008) 551-560
24. Scharf J., Zapletal C., Hess T., et al. Assessment of hepatic perfusion in pigs by pharmacokinetic analysis of dynamic MR images. J Magn Reson Imaging 9 4 (1999) 568-572
25. Materne R., Smith A.M., Peeters F., et al. Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med 47 1 (2002) 135-142
26. Annet L., Materne R., Danse E., et al. Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 229 2 (2003) 409-414
27. Jackson A., Haroon H., Zhu X.P., et al. Breath-hold perfusion and permeability mapping of hepatic malignancies using magnetic resonance imaging and a first-pass leakage profile model. NMR Biomed 15 2 (2002) 164-173
28. Abdullah S.S., Pialat J.B., Wiart M., et al. Characterization of hepatocellular carcinoma and colorectal liver metastasis by means of perfusion MRI. J Magn Reson Imaging 28 2 (2008) 390-395
29. Hagiwara M., Rusinek H., Lee V.S., et al. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging-initial experience. Radiology 246 3 (2008) 926-934
30. Ivancevic M.K., Zimine I., Foxall D., et al. Inflow effect in first-pass cardiac and renal MRI. J Magn Reson Imaging 18 3 (2003) 372-376
31. Burkart D.J., Johnson C.D., Reading C.C., et al. MR measurements of mesenteric venous flow: prospective evaluation in healthy volunteers and patients with suspected chronic mesenteric ischemia. Radiology 194 3 (1995) 801-806
32. de Haen C., Cabrini M., Akhnana L., et al. Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 23 Suppl 1 (1999) S161-S168
33. Korosec F.R., Frayne R., Grist T.M., et al. Time-resolved contrast-enhanced 3D MR angiography. Magn Reson Med 36 3 (1996) 345-351
34. Fink C., Ley S., Kroeker R., et al. Time-resolved contrast-enhanced three-dimensional magnetic resonance angiography of the chest: combination of parallel imaging with view sharing (TREAT). Invest Radiol 40 1 (2005) 40-48
35. Song T, Laine AF, Chen Q, et al. Optimal k-space sampling for dynamic contrast-enhanced MR imaging with an application to MR renography. Magn Reson Med February 19, 2009 [Epub ahead of print].
36. Padhani A.R. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 16 4 (2002) 407-422
37. Evelhoch J.L. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10 3 (1999) 254-259
38. Kuhl C.K., Mielcareck P., Klaschik S., et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?. Radiology 211 1 (1999) 101-110
39. Tofts P.S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7 1 (1997) 91-101
40. Tofts P.S., Brix G., Buckley D.L., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10 3 (1999) 223-232
41. Miyazaki K., Collins D.J., Walker-Samuel S., et al. Quantitative mapping of hepatic perfusion index using MR imaging: a potential reproducible tool for assessing tumour response to treatment with the antiangiogenic compound BIBF 1120, a potent triple angiokinase inhibitor. Eur Radiol 18 7 (2008) 1414-1421
42. Totman J.J., O'Gorman R.L., Kane P.A., et al. Comparison of the hepatic perfusion index measured with gadolinium-enhanced volumetric MRI in controls and in patients with colorectal cancer. Br J Radiol 78 926 (2005) 105-109
43. Wang J., Chen L.T., Tsang Y.M., et al. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol 183 3 (2004) 713-719
44. Materne R., Van Beers B.E., Smith A.M., et al. Non-invasive quantification of liver perfusion with dynamic computed tomography and a dual-input one-compartmental model. Clin Sci (Lond) 99 6 (2000) 517-525
45. Van Beers B.E., Leconte I., Materne R., et al. Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity. AJR Am J Roentgenol 176 3 (2001) 667-673
46. Morgan B., Thomas A.L., Drevs J., et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21 21 (2003) 3955-3964
47. van Laarhoven H.W., Rijpkema M., Punt C.J., et al. Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases. J Magn Reson Imaging 18 3 (2003) 315-320
48. Koh T.S., Thng C.H., Lee P.S., et al. Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced MR imaging with dual-input two-compartment tracer kinetics model. Radiology 249 1 (2008) 307-320 Epub 2008 Aug 2011
49. Peeters F., Annet L., Hermoye L., et al. Inflow correction of hepatic perfusion measurements using T1-weighted, fast gradient-echo, contrast-enhanced MRI. Magn Reson Med 51 4 (2004) 710-717
50. Bokacheva L., Rusinek H., Chen Q., et al. Quantitative determination of Gd-DTPA concentration in T1-weighted MR renography studies. Magn Reson Med 57 6 (2007) 1012-1018
51. Jones R.A., Easley K., Little S.B., et al. Dynamic contrast-enhanced MR urography in the evaluation of pediatric hydronephrosis: part 1, functional assessment. AJR Am J Roentgenol 185 6 (2005) 1598-1607
52. Kim S., Quon H., Loevner L.A., et al. Transcytolemmal water exchange in pharmacokinetic analysis of dynamic contrast-enhanced MRI data in squamous cell carcinoma of the head and neck. J Magn Reson Imaging 26 6 (2007) 1607-1617
53. Bokacheva L., Huang A.J., Chen Q., et al. Single breath-hold T1 measurement using low flip angle TrueFISP. Magn Reson Med 55 5 (2006) 1186-1190
54. Van Beers B.E., Materne R., Annet L., et al. Capillarization of the sinusoids in liver fibrosis: noninvasive assessment with contrast-enhanced MRI in the rabbit. Magn Reson Med 49 4 (2003) 692-699